As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|A Study of the Safety and Efficacy of Pembrolizumab in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma||022||
||Phase 1/Phase 2||Recruiting|
|Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma||716||Melanoma||Phase 3||Recruiting|
|Pembrolizumab as First-line Therapy for Advanced Merkel Cell Carcinoma||913||Merkel Cell Carcinoma||Phase 3||Recruiting|
|Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab Compared to Ipilimumab in Participants With Advanced Melanoma||006||Melanoma||Phase 3||Active, not recruiting|
|Safety and Tolerability of Pembrolizumab + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma||029||
||Phase 1/Phase 2||Active, not recruiting|
|Study of Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma||054||Melanoma||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Versus Chemotherapy in Participants With Advanced Melanoma||002||Malignant Melanoma||Phase 2||Completed|